Kwangdong Pharmaceutical Signs Exclusive Domestic Licensing Agreement with US Ocugen for Retinitis Pigmentosa Gene Therapy Candidate
Kwangdong Pharmaceutical announced on September 17 that it has signed an exclusive domestic licensing agreement with the US-based biotech company Ocugen for "OCU400," a next-generation gene therapy candidate for the treatment of retinitis pigmentosa.
Currently, OCU400 is undergoing evaluation in a global Phase 3 clinical trial, and Ocugen aims to submit a regulatory application to the US Food and Drug Administration (FDA) next year. Kwangdong Pharmaceutical plans to proceed with domestic regulatory procedures based on the global clinical results and approval data.
Retinitis pigmentosa is a rare genetic disease in which the retina is progressively damaged, leading to narrowing of the field of vision and, ultimately, blindness. It is estimated that there are about 7,000 patients in Korea. Through this agreement, Kwangdong Pharmaceutical not only provides patients with a new treatment opportunity but also strengthens its ophthalmology portfolio, alongside existing pipelines for presbyopia and pediatric myopia.
A Kwangdong Pharmaceutical representative said, "We are deeply honored to bring new hope to domestic patients with retinitis pigmentosa," adding, "We will do our utmost to supply the treatment as soon as the clinical trials are completed."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, Kwangdong Pharmaceutical is nurturing ophthalmology as its next growth engine by securing a diverse pipeline, including Brimochol, a candidate for presbyopia treatment; NVK002, a new drug candidate for pediatric myopia; and Raxone, a treatment for rare ophthalmic diseases.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.